Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00706914 · ClinicalTrials.gov registry record · Phase 2
Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
A Phase 2 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 2
- Development phase
- 156
- Enrollment target
NCT00706914 is a Phase 2 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 156 participants.
The verdict
NCT00706914, a Phase 2 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 156 participants
- Enrollment target
Study Summary
This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the evening vs. the FDC once daily in the morning and formoterol fumarate once in the evening vs. formoterol fumarate twice daily. The study will assess pulmonary function and symptoms in patients with moderate to severe COPD.
Interventions
- DRUG Once-daily aclidinium/formoterol
- DRUG Twice-daily formoterol fumarate
- DRUG Placebo to formoterol fumarate
- DRUG Once-daily formoterol fumarate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 156 participants |
| Start Date | 2008-06-30 |
| Est. Completion | 2008-11-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00706914
The ClinicalTrials.gov registry entry for NCT00706914 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 156 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Once-daily aclidinium/formoterol is the first listed.
NCT00706914 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00706914 about?
NCT00706914 is a clinical study titled "Comparison of Aclidinium Bromide and Formoterol Fumarate in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)". This exploratory study will compare the efficacy of the fixed-dose combination (FDC) of aclidinium bromide and formoterol fumarate once daily in the morning and placebo once in the evening vs. the FDC once daily in the morning and formoterol fumarate once in the evening vs. formoterol fumarate twice...
What is the current status of trial NCT00706914?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 156 participants. The study started on 2008-06-30. Estimated completion is 2008-11-11.
What interventions are being tested in trial NCT00706914?
The interventions under investigation include: Once-daily aclidinium/formoterol (DRUG), Twice-daily formoterol fumarate (DRUG), Placebo to formoterol fumarate (DRUG), Once-daily formoterol fumarate (DRUG).
Who is sponsoring clinical trial NCT00706914?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.